The regulation of the inflammasome activity at posttranslational levels (phosphorylation, ubiquitination, de-ubiquitination, proteolytic processing, S-nitrosylation, and ADP-ribosylation) [45]; regulation of NLRP1, caspase-1, and cytokines (IL-18 and IL-1β) [46]; and modulation of anti- and proinflammatory activities of IL-6 [5, 7, 14, 46] might offer innovative therapeutic targets for prostatic tumor-related inflammation. This evidence concerns the gene IL6 and prostate neoplasm.